Dominick Angiolillo, MD
Interventional Cardiology · Jacksonville, FLNPI 1578687844
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $237,939 of the $386,895 with a category attached, or 61.5%. 20 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 29.7% of the total. Among interventional cardiology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 186 payments — averaging $2080.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$115K
- Chiesi USA, Inc.$81K
- E.r. Squibb & Sons, L.L.C.$43K
- Amgen$31K
- Novartis$21K
- Janssen Scientific Affairs, LLC$19K
- plus $77K from 14 others
Across 274 payments — averaging $13,100 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$1.2M
- Janssen Research & Development, LLC$687K
- Amgen$681K
- AstraZeneca$561K
- Sequel Therapeutics, LLC$100K
- Vertex$83K
- plus $319K from 7 others
What the payments were for
- Consulting fees$237,93961%
- Speaking & faculty fees$80,97821%
- Travel & lodging$65,73917%
- Food & beverage$2,2391%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 24 | $114,803 |
| Chiesi USA, Inc. | 28 | $81,030 |
| E.r. Squibb & Sons, L.L.C. | 22 | $43,135 |
| Amgen | 21 | $31,198 |
| Novartis | 7 | $20,679 |
| Janssen Scientific Affairs, LLC | 22 | $19,310 |
| Boehringer Ingelheim International GmbH | 11 | $18,156 |
| Janssen Research & Development, LLC | 18 | $15,113 |
| Astrazeneca UK Limited | 6 | $11,475 |
| CSL Behring | 3 | $9,295 |
| Eli Lilly | 1 | $7,600 |
| AstraZeneca | 2 | $5,370 |
| Idorsia Pharmaceuticals US Inc | 1 | $2,500 |
| Accriva Diagnostics Inc. | 1 | $2,200 |
| Lilly USA, LLC | 1 | $1,752 |
| Novartis Pharma AG | 5 | $1,711 |
| Abbott | 3 | $1,250 |
| Acist Medical Systems, Inc. | 8 | $179 |
| Edwards Lifesciences | 1 | $81 |
| Novo Nordisk | 1 | $59 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$386,895 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 42 | $34,437 |
| EntrestoSacubitril/Valsartan | 14 | $16,384 |
| BrilintaTicagrelor | 19 | $12,277 |
| Repatha SureclickEvolocumab | 21 | $12,022 |
| Atorvastatin Calcium | 225 | $2,038 |
| Ezetimibe | 61 | $1,619 |
| Metoprolol Succinate | 95 | $1,465 |
| Carvedilol | 149 | $1,112 |
| Amlodipine Besylate | 111 | $665 |
| ClopidogrelClopidogrel Bisulfate | 72 | $595 |
| Losartan Potassium | 30 | $324 |
| Rosuvastatin Calcium | 34 | $322 |
| Lisinopril | 65 | $286 |
| Pravastatin Sodium | 14 | $278 |
| Furosemide | 43 | $199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $20,679 | $16,38414 claims |
| AstraZenecaBrilinta | $5,370 | $12,27719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Jacksonville
- Siddharth WayangankarJacksonville$1.2M
- Ruby SatpathyJacksonville$205K
- Bharat GummadiJacksonville$153K
- Raguveer MurthyJacksonville$65K
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.